Project Grant R01AI186786
Award Date
8/15/24
Completion Date
6/30/29
Dollars Obligated
$810K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Washington, DC, USA
Similar Awards
This $1,415,374 federal Project Grant award from the National Institute of Mental Health (CFDA 93.242 Mental Health Research Grants program) aims to evaluate the integration of HIV prevention, including HIV self-testing and pre-exposure prophylaxis (PrEP), into household tuberculosis (TB) contact investigation in Uganda. The study has three key objectives: 1) assess the implementation and effectiveness of home-based HIV self-testing and PrEP initiation versus standard clinic referral during...
This federal Project Grant award of $783,348.00, provided by the National Institute of Nursing Research (NINR) under CFDA Program 93.361 - Nursing Research, supports the implementation and evaluation of an HIV status-neutral, nurse-led intervention to increase equity in clinical outcomes for male HIV self-testers in Tanzania. The key products and services to be delivered through this grant include: 1) tailoring the STEP+CBNIMART intervention to better meet the needs of heterosexual male HIV...
This federal Project Grant award, with funding of $431,712.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research), aims to improve HIV testing among children under five in rural Uganda. The project has two key objectives: To determine barriers and facilitators to pediatric HIV testing and adapt a traditional healer-facilitated HIV testing program for children aged 18 months to 5 years. This will involve interviews with...
This $825,988 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to leverage social determinants data and spatial data science to reduce HIV incidence in Ending the HIV Epidemic (EHE) counties across the United States. The key products and services to be delivered under this grant include: Developing transportation-based measures of PrEP accessibility at the county and zip code levels using...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support the development of a novel universal rapid test for HIV diagnosis. IGE Immunodiagnostics & Therapeutics, LLC, a minority-owned small business, will receive $294,948 to adapt their existing HIV ELISA test into a 5th generation antigen/antibody combination rapid test format. The goal is to create a simple, rapid,...
This federal Project Grant award, valued at $1,564,570 and awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify drivers of genital inflammation and HIV acquisition in women living in sub-Saharan Africa. The prime awardee, The General Hospital Corporation (doing business as Massachusetts General Hospital), will conduct this 5-year research project in collaboration with...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support a pilot study to integrate a Universal Test-and-Connect (UTC) strategy for delivering comprehensive HIV services in emergency department (ED) settings in South Africa. The $582,959 award will fund three main objectives over a three-year period: 1) integrating HIV assessment into routine ED care to define...
This Project Grant award, with a total funding amount of $667,848, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award will support research to investigate the molecular and phenotypic features of pre-existing HIV gp120-specific B cells, and how these B cell populations respond to HIV vaccination in high-risk individuals, including those using pre-exposure prophylaxis (PrEP). The...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports a randomized controlled trial to evaluate strategies for engaging the social networks of current PrEP clients from high-HIV incidence communities in Miami, Florida. The $2,155,836 award will fund a 5-year study to compare the effectiveness, cost, and implementation factors of two approaches: 1) a...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $381,487 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Maryland, Baltimore. The grant, titled "Scaling Comprehensively Access to Long-Acting for an Effective Use of PrEP (SCALE-UP)", aims to assess the real-world implementation of long-acting injectable cabotegravir (CAB-LA) for HIV pre-exposure prophylaxis (PrEP) among adolescent girls and young...